The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

Xavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...